Anti-Migraine Drugs Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: Eli Lilly, Abbott Laboratories, Eisai, Allergan

Registering a CAGR of 8.9% over the forecast period, the market value of Anti-Migraine Drugs is expected to reach US$ 12.1 billion in the year 2027.

Anti-Migraine Drugs Market Overview

A migraine is a frequent neurological illness that causes throbbing, pounding headaches that vary in intensity on one side of the brain. Tetracycline, an antibiotic that works by preventing bacteria from growing, can produce acute migraine headaches, as well as nausea, vomiting, diarrhoea, and a loss of appetite. Migraine medications are intended to lessen the severity of migraine headaches. Aura signs, such as flashing lights or zigzag lines, can occasionally precede migraine headaches. If your migraine with aura is accompanied by nausea and vomiting, you should take anti-nausea medication. Opioid-containing medications, such as oxycontin, Vicodin, Percocet, and others, prevent migraine central sensitization from reversing.

The drugs used to treat migraines are divided into two types: abortive and preventative. Preventive medications are used to reduce the number of migraine attacks whereas abortive meds are used to interrupt an existing migraine attack. The increased prevalence of migraines, rising healthcare expenditures, and rising awareness about anti-migraine pharmaceuticals are some of the reasons driving the Anti-Migraine Drugs Market growth between 2022 and 2027.

The report aspects discussed the profile of the top manufacturers of the global Anti-Migraine Drugs market. These aspects include financial status of major companies, trending advancements and entire market scenario. Growth of the report have examined Anti-Migraine Drugs Market production, demand and growth potential, geographic analysis, as well as current market developments in various regions and countries.

Anti-Migraine Drugs Market Growth Drivers

• The Increasing Prevalence of Migraine has benefitted the consumption of anti-migraine drugs: According to the World Health Organization (WHO), present migraine affects 10% of individuals worldwide, while lifetime migraine affects 1 in every 7 adults. Approximately 3000 migraine attacks per million persons worldwide occur every day and it is ranked as the 19th most common reason for disability by WHO. Factors such as increasing work pressure, anxiety, stress, and changes in lifestyles are some of the causes for the increasing prevalence of migraine globally.


• Increased awareness of the Anti-migraine drug has readily aided the market growth: The rise in public awareness regarding the use of anti-migraine drugs, as well as the expanding migraine population, are propelling the market for anti-migraine drugs forward. Many organizations are working towards spreading awareness about Anti-nausea drugs globally.

Industry News and Updates:

Sept. 28, 2021-- FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine--

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults.1 QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migraine.2

22 October 2019 - Lundbeck completes the acquisition of Alder BioPharmaceuticals - a company committed to transforming migraine treatment and prevention--

H. Lundbeck A/S (Lundbeck) today announced that it has successfully completed the acquisition of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) (“Alder”) a migraine-focused company based in Bothell, Washington, for an aggregate cash consideration of up to approximately USD 1.95 billion (DKK 13 billion) net of cash, on a fully diluted basis. The transaction, which was announced on 16 September 2019, significantly accelerates and strengthens the build of Lundbeck’s pipeline. 

What are the major Applications, Types and Regions for Anti-Migraine Drugs Market?

Market is segmented based on the type, applications, companies and regions.

By Type, it is segmented into

• Triptans


• Ergots


• Others

By Application, it is segmented into

• Women


• Men

Anti-Migraine Drugs Market Regional Analysis

Geographically, the Anti-Migraine Drugs market may be divided into North America, Europe, Asia-Pacific, South America, and the Rest of the World. Because to the rising prevalence of migraine and increasing use of anti-migraine and anti-nausea medications, North America held a strong market share of 40.5% in 2021 when compared to its peers. Migraine affects roughly 37 million men, women, and children in the United States, according to the American Migraine Association. A migraine sufferer can be found in one out of every four households.

Due to an increase in demand for better healthcare facilities, raising awareness about the effectiveness of anti-migraine drugs, untapped investment potential, and rising prevalence of migraine, Asia-Pacific is expected to be the fastest-growing region, with a CAGR of 6.2 percent over the forecast period of 2022-2027. Because of its fastest-growing pharmaceutical sector, China now dominates and is expected to continue to dominate the Asia-Pacific migraine treatment market during the projection period. Over the projected period, China's government's pharma policies and incentives aimed at reforming the pharmaceutical industry are expected to boost market growth.

• North America
  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • Latin America
  
  
  
  

The Anti-Migraine Drugs Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Anti-Migraine Drugs Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

What is our Anti-Migraine Drugs Market report scope?

Key Takeaways from this Anti-Migraine Drugs Report

• Evaluate Anti-Migraine Drugs market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.


• Understand the different dynamics influencing the market - growth driving factors, specific challenges and hidden opportunities.


• Get in-depth insights on your competitor performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis and more.


• Analyze the sales and distribution channels across geographies to enhance top-line revenues.


• Understand the demanding supply chain with a deep dive on the value augmentation at each, in order to optimize value and bring efficiencies in your processes.


• Get a quick outlook on the Anti-Migraine Drugs market entropy - M&A's, deals, partnerships, product launches of all key players for the past 5 years.


• Evaluate the import-export statistics, supply-demand and competitive landscape for more than top 20 countries globally for the market.

Frequently Asked Questions

What is the growth rate of Anti-Migraine Drugs Market?

The Anti-Migraine Drugs Market is growing at a CAGR of 8.9% over the next 5 years.

Who are the key players in Anti-Migraine Drugs Market?

Eli Lilly, Abbott Laboratories, Eisai, Allergan, Endo, GlaxoSmithKline, Impax Laboratories, Pfizer, AstraZeneca, Bayer, Johnson & Johnson, Merck, Teva, Amgen

What are the significant types of Anti-Migraine Drugs Market?

Triptans, Ergots, Others

What are the major end-use applications of Anti-Migraine Drugs Market?

Women, Men

All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.